ijms-logo

Journal Browser

Journal Browser

Advancing Precision Medicine in Urological Cancers: Integrating Multi-Omics and Optimizing Therapeutic Approaches

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 January 2026 | Viewed by 133

Special Issue Editor


E-Mail
Guest Editor
Department of Pharmaceutical Sciences, University of Puerto Rico Medical Sciences Campus & Cancer Biology, UPR Comprehensive Cancer Center, San Juan, PR 00936, USA
Interests: prostate cancer; integrating multi-omics

Special Issue Information

Dear Colleagues,

Urological cancers, including bladder cancer, kidney cancer, prostate cancer, testicular cancer, and penile cancer, remain some of the most prevalent and challenging malignancies, with outcomes varying significantly across patients due to genetic, molecular, and clinical factors. This Special Issue, "Advancing Precision Medicine in Urological Cancers: Integrating Multi-Omics and Optimizing Therapeutic Approaches," aims to explore cutting-edge research and innovations that bridge the gap between molecular discoveries and personalized therapeutic strategies. The integration of multi-omics—including genomics, transcriptomics, proteomics, and metabolomics—provides an unparalleled opportunity to refine risk stratification, identify novel therapeutic targets, and optimize treatment strategies. By highlighting advances in pharmacogenomics and biomarker discovery, this Special Issue will emphasize precision oncology tools that guide tailored interventions. This Special Issue will also address the role of cancer-specific genomic variations and clinical factors in disease incidence, progression, and treatment response. We invite submissions that explore a range of topics, including multi-omics approaches for characterizing disease heterogeneity, mechanisms of treatment resistance, liquid biopsy innovations, and strategies to optimize the accessibility and impact of precision medicine. This Special Issue will serve as a platform for interdisciplinary collaboration and a resource for advancing personalized care in urological cancers.

Dr. Magaly Martinez-Ferrer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • proteomics
  • metabolomics
  • precision medicine
  • biomarker

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 1870 KiB  
Review
Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment
by Marta Lopez-Valcarcel, Fernando Lopez-Campos, Juan Zafra-Martín, Irene Cienfuegos Belmonte, José Daniel Subiela, María Ruiz-Vico, Sandra Fernandez Alonso, Jose Angel Garcia Cuesta and Felipe Couñago
Int. J. Mol. Sci. 2025, 26(16), 7667; https://doi.org/10.3390/ijms26167667 - 8 Aug 2025
Abstract
Prostate-specific antigen (PSA) has been the primary biomarker used for the detection and monitoring of prostate cancer for decades. However, its limited specificity and prognostic accuracy have led to the development of novel molecular and imaging biomarkers aimed at improving the clinical characterization [...] Read more.
Prostate-specific antigen (PSA) has been the primary biomarker used for the detection and monitoring of prostate cancer for decades. However, its limited specificity and prognostic accuracy have led to the development of novel molecular and imaging biomarkers aimed at improving the clinical characterization of localized disease. This review critically examines recent advances in urinary biomarkers (e.g., PCA3, SelectMDx), tissue-based genomic assays (Oncotype DX Prostate, Prolaris, Decipher), and imaging techniques such as multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography (PET-PSMA). We evaluate their diagnostic performance, prognostic value, and clinical utility in risk stratification and individualized treatment decision-making. Methodological and clinical barriers to their routine implementation are also discussed. Current evidence supports the multidisciplinary integration of these biomarkers to overcome the limitations of PSA, improve biopsy decision-making, better distinguish indolent from aggressive tumors, and optimize therapeutic strategies. Finally, future research directions aimed at validating and incorporating emerging biomarkers into clinical practice are outlined, with the goal of improving outcomes in patients with localized prostate cancer. Full article
Show Figures

Graphical abstract

Back to TopTop